Defence Therapeutics Announces Grant of Restricted Stock Units
Defence Therapeutics (OTCQB: DTCFF) announced that its board approved a grant of 200,000 incentive restricted stock units (RSUs) to CEO and director Sebastien Plouffe, vesting immediately on April 24, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Defence Therapeutics (OTCQB: DTCFF) announced that its board approved a grant of 200,000 incentive restricted stock units (RSUs) to CEO and director Sebastien Plouffe, vesting immediately on April 24, 2026. Each RSU converts to one common share and expires April 24, 2027, subject to the Omnibus Incentive Plan and securities law hold periods.
Details
News Market Reaction – DTCFF
On Apr 27, the first trading day after this news, DTCFF closed 2.02% above the previous close.
Data tracked by StockTitan Argus for the Apr 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, wishes to announce that the board of directors of the Company approved the grant of 200,000 incentive restricted stock units ("RSUs") to Mr. Sebastien Plouffe, CEO and Director of the Company, vesting immediately. Each RSU entitles the holder thereof to receive one common share of the Company expiring on April 24, 2027, subject to the terms of the Omnibus Incentive Plan of the Company and applicable securities law hold periods.
About Defence Therapeutics:
Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.
For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294219
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.